{"id":408378,"date":"2021-01-05T08:03:31","date_gmt":"2021-01-05T13:03:31","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=408378"},"modified":"2021-01-05T08:03:31","modified_gmt":"2021-01-05T13:03:31","slug":"oncternal-therapeutics-to-participate-in-fireside-chat-at-h-c-wainwright-bioconnect-2021-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-fireside-chat-at-h-c-wainwright-bioconnect-2021-conference\/","title":{"rendered":"Oncternal Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect 2021 Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p>SAN DIEGO, Jan.  05, 2021  (GLOBE NEWSWIRE) &#8212; Oncternal Therapeutics (Nasdaq: ONCT), today announced that James Breitmeyer, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat hosted by H.C. Wainwright on Monday, January 11, 2021. The discussion may cover Oncternal\u2019s recent progress, upcoming catalysts, and plans for 2021. Please see additional details below:<\/p>\n<p>\n        <em><br \/>\n          <u>H.C. Wainwright BioConnect 2021 Conference (Virtual)<\/u><br \/>\n        <\/em>\u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0<\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:10%;width:10%;min-width:10%\">Title:<\/td>\n<td style=\"max-width:90%;width:90%;min-width:90%\">\n            <em><br \/>\n              <strong>Oncternal Therapeutics (ONCT) Fireside Chat<\/strong><br \/>\n            <\/em>\n          <\/td>\n<\/tr>\n<tr>\n<td>Date:<\/td>\n<td>Monday, January 11<sup>th<\/sup> 2021<\/td>\n<\/tr>\n<tr>\n<td>Time:<\/td>\n<td>On-demand starting at 6am EST<\/td>\n<\/tr>\n<tr>\n<td>Presenter:<\/td>\n<td>James Breitmeyer,\u00a0<em>President &amp; CEO<\/em><\/td>\n<\/tr>\n<tr>\n<td>\n            <em><br \/>\n              <br \/>Webcasting Link:<\/em><br \/>\n            \n          <\/td>\n<td>\n            <a href=\"https:\/\/journey.ct.events\/view\/0952e01c-36d3-4ded-87b9-945b71112ce1\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><br \/>\n              <br \/>\ufeff<em>Click Here<\/em><\/a>\n          <\/td>\n<\/tr>\n<\/table>\n<p>\n        <strong>Replay Link: <\/strong><br \/>\n        <br \/>A replay will be accessible on the Events &amp; Presentations page of the Investors section on the Company\u2019s website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=RBkP4jMTNlyDX9L3THwdYy3mwvcZOAOFBMyoXg3_Jh2xUEm_Cka-BsDajS3bp3IZcX6HW9Y5l10z0d6WuH-u3JRsEQXkJAq7luhewLAcF9KQR6_1EQ_X2_CoUrmm_l_Yiws2prC1ubkxORVR_IiAHTAuENWfeJiTtFF0334ShDZ3MoSV0bZRyUygN36YYLc4miZiIndpjfxUAHfZgF4EOQ==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>https:\/\/investor.oncternal.com\/news-and-events\/events-presentations<\/u><\/a><\/p>\n<p>\n        <strong><br \/>\n          <strong>About Oncternal Therapeutics<br \/><\/strong><br \/>\n        <\/strong>Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer generation or progression. The clinical pipeline includes <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vlZTAL6Irh939DUR9zzPvAUOPswHLVu_1lTo6ECmUTYeEEB3x2vflOtKHDsH2TO8i7NzT7-nKtRfoYhcsJ7TDJV_J8gndRG5vSHPQqD_H57SUaqv2eqkyzBWiIFFfb_c0OLdH2Gh8XMLMOZM9a9jkYXqIqcWwkUgruSZ_-0IFVHvMO9r8JOAz0m7Mln9262DT89LtVn9WSHDb-8wiknkWHYpu3Lo3upPzA3zaTAy_kxlcHT9OqmVInvx9UWpUhoxwdRm8aMOvBVkzifwu2DV5wY08vljSsBGPK3OPl0YGYs1tLrhZnM8TgQQhSpHIqKI_yG4UX-1Q0XA3LQpRAVSnSeGM2YfZcJij9w0vYoPNb8RkXq-jvxgbaoiy4lk8CSpLn6acyQ5-MIDN-91nz_36Bk0bAoW92Hm7-of1WPIZ2efC9RaIolGFU9OVJRbAwLt\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>cirmtuzumab<\/u><u>,<\/u><\/a> an investigational monoclonal antibody designed to inhibit the ROR1 pathway, a type I tyrosine kinase-like orphan receptor, that is being evaluated in a Phase 1\/2 clinical trial in combination with ibrutinib for the treatment of patients with mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL) and in an investigator-sponsored, Phase 1b clinical trial in combination with paclitaxel for the treatment of women with HER2-negative metastatic or locally advanced, unresectable breast cancer. The clinical pipeline also includes <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=8TCm28YjWGYvOWMZExeOBSnzJKZ6Eo_fRiTNJVGpoevbfyhSKXozxfny7GwhLHJmaBapGCY-z8hL2K7BeUMDmic2woJL5Ng2eNaSpOlgWNI=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>TK216<\/u><u>,<\/u><\/a> an investigational targeted small-molecule inhibitor of the ETS family of oncoproteins, that is being evaluated in a Phase 1 clinical trial for patients with Ewing sarcoma alone and in combination with vincristine chemotherapy. In addition, Oncternal has a program utilizing the cirmtuzumab antibody backbone to develop a <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=KqvmqT0y8vSQsbov7Q8Qo41MsAP25pqCd474MqnQnqXt7slFeEXYBXdtF5ZWBImrVrUr8IvL6Xg_Lgd2YBRedOOVeOvgIAELYnBXrvIXiQg=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>CAR-T<\/u><\/a> therapy that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors. More information is available at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=aWKQtsGyv0qOpU2UTNbfB2xOp0iwydONfDwuvOXjRozz5Nwb4ot3uM6XEOsEmq5VNvEEreuoQfe5ESY5hKFErACiXOi7neYJaqo6JAgvxFNAYwwsv2kx-grlXTcYuQJci9TDxtVsv7Fyk2HEiAHIIMGE2Ss2nJ7o7K-yAB-0zewKYFT-WPzzCtzDwZ_I12ZPCmB1f4tsFYTyssEmhQgKh180tjkamvkn0-rnSLQo4uu4DDm4stAWdYwKDCLZseSqzuR0w35cva5e49B9vzcsyAyWiA8uFz77y24TN2Ul2Feb6tawYvdB0dSQgROIeVuQ8nONwPT06Ecen9i98wVnsFy54GCYLfYIIj55_NpwyTlIRtV8ebtQuOVgD-HGe6k_xXsG6XJNWxTVS3OxHCEY2KJDHuuUIGjE1PR28ysUna1E11_l9yRx7sY5awo6cfGv\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>www.oncternal.com<\/u><u>.<\/u><\/a><\/p>\n<p>\n        <strong>Oncternal Contacts:<\/strong>\n      <\/p>\n<p>\n        <strong>Company Contact<\/strong><br \/>\n        <br \/>Richard Vincent <br \/>858-434-1113<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=l8_gR9kPFaxLPwGIpscB8AY9p29x5ks3oQqF8Q_7Kx4e3t5SVMw2fgKfa6Wa4VHgQytrOgX0i8Lb7Lokf3bYzt_H_GTrywYxY6AY5HEhxl4=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>rvincent@oncternal.com<\/u><\/a><\/p>\n<p>\n        <strong>Investor Contact<\/strong><br \/>\n        <br \/>Corey Davis, Ph.D. \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0<br \/>LifeSci Advisors \u00a0 \u00a0<br \/>212-915-2577\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0<br \/><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xe_t4w8fWRlbh9g1XcdQMGjm_rJEZfJ3If_J-wG--WlZr1Ew0xgzipSc5Pca9TUBKMkAA5_k9ohH2gNxRBSZr8KND83NHK1JN5X9p_n01BLT98FvsW0gcH3GWBMg_3R5\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">cdavis@lifesciadvisors.com<\/a><\/u><\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDU0MCMzOTA0NTcyIzUwMDA3NDE2MQ==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/63bf03be-f127-4089-8962-ef9da3845ac3\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) &#8212; Oncternal Therapeutics (Nasdaq: ONCT), today announced that James Breitmeyer, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat hosted by H.C. Wainwright on Monday, January 11, 2021. The discussion may cover Oncternal\u2019s recent progress, upcoming catalysts, and plans for 2021. Please see additional details below: H.C. Wainwright BioConnect 2021 Conference (Virtual) \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0 Title: Oncternal Therapeutics (ONCT) Fireside Chat Date: Monday, January 11th 2021 Time: On-demand starting at 6am EST Presenter: James Breitmeyer,\u00a0President &amp; CEO Webcasting Link: \ufeffClick Here Replay Link: A replay will be accessible on the Events &amp; Presentations page of the Investors section &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-fireside-chat-at-h-c-wainwright-bioconnect-2021-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Oncternal Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect 2021 Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-408378","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Oncternal Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect 2021 Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-fireside-chat-at-h-c-wainwright-bioconnect-2021-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Oncternal Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect 2021 Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) &#8212; Oncternal Therapeutics (Nasdaq: ONCT), today announced that James Breitmeyer, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat hosted by H.C. Wainwright on Monday, January 11, 2021. The discussion may cover Oncternal\u2019s recent progress, upcoming catalysts, and plans for 2021. Please see additional details below: H.C. Wainwright BioConnect 2021 Conference (Virtual) \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0 Title: Oncternal Therapeutics (ONCT) Fireside Chat Date: Monday, January 11th 2021 Time: On-demand starting at 6am EST Presenter: James Breitmeyer,\u00a0President &amp; CEO Webcasting Link: \ufeffClick Here Replay Link: A replay will be accessible on the Events &amp; Presentations page of the Investors section &hellip; Continue reading &quot;Oncternal Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect 2021 Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-fireside-chat-at-h-c-wainwright-bioconnect-2021-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-05T13:03:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDU0MCMzOTA0NTcyIzUwMDA3NDE2MQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-participate-in-fireside-chat-at-h-c-wainwright-bioconnect-2021-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-participate-in-fireside-chat-at-h-c-wainwright-bioconnect-2021-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Oncternal Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect 2021 Conference\",\"datePublished\":\"2021-01-05T13:03:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-participate-in-fireside-chat-at-h-c-wainwright-bioconnect-2021-conference\\\/\"},\"wordCount\":356,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-participate-in-fireside-chat-at-h-c-wainwright-bioconnect-2021-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMDU0MCMzOTA0NTcyIzUwMDA3NDE2MQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-participate-in-fireside-chat-at-h-c-wainwright-bioconnect-2021-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-participate-in-fireside-chat-at-h-c-wainwright-bioconnect-2021-conference\\\/\",\"name\":\"Oncternal Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect 2021 Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-participate-in-fireside-chat-at-h-c-wainwright-bioconnect-2021-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-participate-in-fireside-chat-at-h-c-wainwright-bioconnect-2021-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMDU0MCMzOTA0NTcyIzUwMDA3NDE2MQ==\",\"datePublished\":\"2021-01-05T13:03:31+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-participate-in-fireside-chat-at-h-c-wainwright-bioconnect-2021-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-participate-in-fireside-chat-at-h-c-wainwright-bioconnect-2021-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-participate-in-fireside-chat-at-h-c-wainwright-bioconnect-2021-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMDU0MCMzOTA0NTcyIzUwMDA3NDE2MQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMDU0MCMzOTA0NTcyIzUwMDA3NDE2MQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncternal-therapeutics-to-participate-in-fireside-chat-at-h-c-wainwright-bioconnect-2021-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Oncternal Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect 2021 Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Oncternal Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect 2021 Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-fireside-chat-at-h-c-wainwright-bioconnect-2021-conference\/","og_locale":"en_US","og_type":"article","og_title":"Oncternal Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect 2021 Conference - Market Newsdesk","og_description":"SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) &#8212; Oncternal Therapeutics (Nasdaq: ONCT), today announced that James Breitmeyer, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat hosted by H.C. Wainwright on Monday, January 11, 2021. The discussion may cover Oncternal\u2019s recent progress, upcoming catalysts, and plans for 2021. Please see additional details below: H.C. Wainwright BioConnect 2021 Conference (Virtual) \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0 Title: Oncternal Therapeutics (ONCT) Fireside Chat Date: Monday, January 11th 2021 Time: On-demand starting at 6am EST Presenter: James Breitmeyer,\u00a0President &amp; CEO Webcasting Link: \ufeffClick Here Replay Link: A replay will be accessible on the Events &amp; Presentations page of the Investors section &hellip; Continue reading \"Oncternal Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect 2021 Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-fireside-chat-at-h-c-wainwright-bioconnect-2021-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-05T13:03:31+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDU0MCMzOTA0NTcyIzUwMDA3NDE2MQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-fireside-chat-at-h-c-wainwright-bioconnect-2021-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-fireside-chat-at-h-c-wainwright-bioconnect-2021-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Oncternal Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect 2021 Conference","datePublished":"2021-01-05T13:03:31+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-fireside-chat-at-h-c-wainwright-bioconnect-2021-conference\/"},"wordCount":356,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-fireside-chat-at-h-c-wainwright-bioconnect-2021-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDU0MCMzOTA0NTcyIzUwMDA3NDE2MQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-fireside-chat-at-h-c-wainwright-bioconnect-2021-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-fireside-chat-at-h-c-wainwright-bioconnect-2021-conference\/","name":"Oncternal Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect 2021 Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-fireside-chat-at-h-c-wainwright-bioconnect-2021-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-fireside-chat-at-h-c-wainwright-bioconnect-2021-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDU0MCMzOTA0NTcyIzUwMDA3NDE2MQ==","datePublished":"2021-01-05T13:03:31+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-fireside-chat-at-h-c-wainwright-bioconnect-2021-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-fireside-chat-at-h-c-wainwright-bioconnect-2021-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-fireside-chat-at-h-c-wainwright-bioconnect-2021-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDU0MCMzOTA0NTcyIzUwMDA3NDE2MQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMDU0MCMzOTA0NTcyIzUwMDA3NDE2MQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncternal-therapeutics-to-participate-in-fireside-chat-at-h-c-wainwright-bioconnect-2021-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Oncternal Therapeutics to Participate in Fireside Chat at H.C. Wainwright BioConnect 2021 Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/408378","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=408378"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/408378\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=408378"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=408378"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=408378"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}